 |
ImmunityBio
Last updated: July 31, 2025
Patrick Soon-Shiong, CEO
USA | Funding: $1.4B (+)
Website: https://immunitybio.com
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
Website: https://immunitybio.com
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
